My former @US_FDA colleagues have published a very useful article showing how little information becomes public when FDA tells a drug company that its application is not complete enough for review. (1/4) https://pubmed.ncbi.nlm.nih.gov/33587091/
It follows on the heels of our previous paper showing similarly that information in letters declining approval for drugs mostly never sees the light of day. (2/4) https://pubmed.ncbi.nlm.nih.gov/26063327/
Interestingly, when companies file new applications (i.e., good news for investors), the public is almost always made aware. (3/4) https://pubmed.ncbi.nlm.nih.gov/31157824/
The @US_FDA should ensure that researchers, clinicians, and investors have access to all this information – but the agency currently regards all of it as confidential. (4/4)